AU6877991A - A method of inactivating human immunodeficiency virus - Google Patents
A method of inactivating human immunodeficiency virusInfo
- Publication number
- AU6877991A AU6877991A AU68779/91A AU6877991A AU6877991A AU 6877991 A AU6877991 A AU 6877991A AU 68779/91 A AU68779/91 A AU 68779/91A AU 6877991 A AU6877991 A AU 6877991A AU 6877991 A AU6877991 A AU 6877991A
- Authority
- AU
- Australia
- Prior art keywords
- immunodeficiency virus
- human immunodeficiency
- inactivating human
- inactivating
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44223489A | 1989-11-28 | 1989-11-28 | |
US442234 | 1989-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6877991A true AU6877991A (en) | 1991-06-26 |
Family
ID=23756040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU68779/91A Abandoned AU6877991A (en) | 1989-11-28 | 1990-11-28 | A method of inactivating human immunodeficiency virus |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6877991A (en) |
WO (1) | WO1991007989A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0686043B1 (en) * | 1993-02-24 | 1999-06-23 | WANG, Jui, H. | Compositions and methods of application of reactive antiviral polymers |
DE19513888A1 (en) * | 1995-04-19 | 1996-10-24 | Focke & Co | Method and device for applying markings, in particular color markings, to film webs |
DE19847362A1 (en) * | 1998-10-14 | 2000-04-20 | Deutsches Krebsforsch | New polycyclic aromatic compound-protein conjugates, useful for detection and/or treatment of diseased tissue, e.g. tumors or inflammation sites |
JP2004538342A (en) * | 2001-03-27 | 2004-12-24 | フイルメニツヒ ソシエテ アノニム | Compounds for controlled release of active compounds |
EP1281767A3 (en) * | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
AU2004289953B2 (en) | 2003-06-18 | 2008-09-25 | Genelux Corporation | Modified recombinant vaccina viruses and other microorganisms, uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63310830A (en) * | 1987-06-10 | 1988-12-19 | Meiji Seika Kaisha Ltd | Antiretroviral agent |
-
1990
- 1990-11-28 AU AU68779/91A patent/AU6877991A/en not_active Abandoned
- 1990-11-28 WO PCT/CA1990/000423 patent/WO1991007989A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1991007989A1 (en) | 1991-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5726694A (en) | Human immunodeficiency virus decoy | |
AU4750390A (en) | Virus inactivated blood product and method | |
AU5789290A (en) | Grasping forceps | |
AU7746487A (en) | Surgical prosthesis | |
AU5980790A (en) | Prosthesis | |
AU4028895A (en) | Vaccine and treatment method of Human Immunodeficiency Virus | |
ZA936592B (en) | Nutrition for persons infected with human immunodeficiency virus | |
AU3413389A (en) | Method of treating retrovirus infection | |
AU6068290A (en) | Invalid walker | |
AU5449590A (en) | Anti-hiv drug | |
AU5848794A (en) | Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use | |
AU3775789A (en) | A method of evaluating recombinant vaccines against immunodeficiency virus | |
AU6291290A (en) | Prosthesis | |
AU5568290A (en) | Method of suppressing hiv infection | |
US5011841B1 (en) | Treatment of depression | |
AU6877991A (en) | A method of inactivating human immunodeficiency virus | |
AU3836489A (en) | Treatment of immunodeficiency | |
AU3964789A (en) | Filtering procedure | |
AU5836390A (en) | Human lymphoma-associated virus | |
AU4034289A (en) | Disposable glove | |
AU7516494A (en) | Oligomers for modulating human immunodeficiency virus | |
EP0414569A3 (en) | Three-liquid-phase epoxidation of perfluoroolefins | |
AU5306590A (en) | Method of killing pests | |
AU7737991A (en) | Medical uses of m-csf | |
AU5940890A (en) | Prosthetic limb |